For research use only. Not for therapeutic Use.
Fosfenopril (Fosinoprilat) is a potent angiotensin converting enzyme (ACE) inhibitor. Fosfenopril alleviates lipopolysaccharide (LPS)-induced inflammation by inhibiting TLR4/NF-κB signaling in monocytes[1][2].
Fosfenopril (0-10 μM, 5 min) inhibits the expression of TLR4 which is elevated by LPS[1].
Fosfenopril (0-10 μM, 1 h)attenuates the expression of NF-κB which is activated by LPS[1].
Fosfenopril inhibits LPS-induced cytokines (IL-6, IL-1β, and TNF-α) expression[1].
Fosfenopril (0.5 mg/kg bolus plus 0.1 mg/kg/min, IV, once) increases p-aminohippurate (PAH) clearance and glomerular filtration rate (GFR) in dogs[3].
| Catalog Number | R044677 |
| CAS Number | 95399-71-6 |
| Synonyms | (2S,4S)-4-cyclohexyl-1-[2-[hydroxy(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid |
| Molecular Formula | C23H34NO5P |
| Purity | ≥95% |
| InChI | InChI=1S/C23H34NO5P/c25-22(17-30(28,29)14-8-7-11-18-9-3-1-4-10-18)24-16-20(15-21(24)23(26)27)19-12-5-2-6-13-19/h1,3-4,9-10,19-21H,2,5-8,11-17H2,(H,26,27)(H,28,29)/t20-,21+/m1/s1 |
| InChIKey | WOIWWYDXDVSWAZ-RTWAWAEBSA-N |
| SMILES | C1CCC(CC1)C2CC(N(C2)C(=O)CP(=O)(CCCCC3=CC=CC=C3)O)C(=O)O |
| Reference | [1]. Yang S, et al. Fosinoprilat alleviates lipopolysaccharide (LPS)-induced inflammation by inhibiting TLR4/NF-κB signaling in monocytes. Cell Immunol. 2013 Jul-Aug;284(1-2):182-6. [2]. DeForrest JM, et al. Fosinopril, a phosphinic acid inhibitor of angiotensin I converting enzyme: in vitro and preclinical in vivo pharmacology. J Cardiovasc Pharmacol. 1989 Nov;14(5):730-6. [3]. DeForrest JM, et al. Blood pressure lowering and renal hemodynamic effects of fosinopril in conscious animal models. J Cardiovasc Pharmacol. 1990 Jul;16(1):139-46. |
